Fhit, Mlh1, P53 and phenotypic expression in the early stage of colorectal neoplasms

Oncology Reports

Volumn 19, Issue 1, 2008, Pages 41-47

  Yasugi, Akiko ^a   Yashima, Kazuo ^a   Hara, Akihito ^a   Koda, Masaharu ^a   Kawaguchi, Koichiro ^a   Harada, Kenichi ^a   Andachi, Hironobu ^a   Murawaki, Yoshikazu ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Colorectal cancer; Fhit; Mlh1; Mucin phenotype; p53

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; FRAGILE HISTIDINE TRIAD PROTEIN; GENE PRODUCT; MUCIN 2; PROTEIN HGM; PROTEIN MLH1; PROTEIN MSH2; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CARCINOGENESIS; COLORECTAL ADENOMA; COLORECTAL CANCER; COLORECTAL CARCINOMA; CONTROLLED STUDY; EARLY CANCER; ENDOSCOPIC SURGERY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; INCIDENCE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 38749092528     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.19.1.41     Document Type: Article

References (45)

1. Vogelstein B, Fearon ER, Hamilton SR, et al: Genetic alterations during colorectal-tumor development. N Engl J Med 319: 525-532, 1998.
2. Kuramoto S and Oohara T: Minute cancers arising de novo in the human large intestine. Cancer 61: 829-834, 1988.
3. Muto T, Kamiya J, Sawada T, et al: Small 'flat adenoma' of the large bowel with special reference to its clinicopathologic features. Dis Colon Rectum 28: 847-851, 1985.
4. Shimoda T, Ikegami M, Fujisaki J, Matsuj T, Aizawa S and Ishikawa E: Early colorectal carcinoma with special reference to its development de novo. Cancer 64: 1138-1146, 1989.
5. Kudo S, Kashida H, Nakajima T, Tamura S and Nakajo K: Endoscopic diagnosis and treatment of early colorectal cancer. World J Surg 21: 694-701, 1997.
6. Huebner K and Croce CM: cancer and the FRA3B/FHIT fragile locus: it's a HIT. Br J Cancer 88: 1501-1506, 2003.
7. Ohta M, Inoue H, Cotticelli MG, et al: The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84: 587-597, 1996.
8. Hao XP, Willis JE, Pretlow TG, Rao JS, MacLennan GT, Talbot IC and Pretlow TP: Loss of fragile histidine triad expression in colorectal carcinomas and premalignant lesions. Cancer Res 60: 18-21, 2000.
9. Kuwai T, Tanaka S, Kaio E, et al: Clinical significance of Fhit expression in development of colorectal carcinoma of various macroscopic types. Int J Mol Med 12: 437-442, 2003.
10. Mimori K, Ishii H, Nagahara H, et al: FHIT is up-regulated by inflammatory stimuli and inhibits prostaglandin E2-mediated cancer progression. Cancer Res 66: 2683-2690, 2006.
11. Andachi H, Yashima K, Koda M, et al: Reduced Fhit expression is associated with mismatch repair deficiency in human advanced colorectal carcinoma. Br J Cancer 87: 441-445, 2002.
12. Mori M, Mimori K, Masuda T, Yoshinaga K, Yamashita K, Matsuyama A and Inoue H: Absence of Msh2 protein expression is associated with alteration in the FHIT locus and Fhit protein expression in colorectal carcinoma. Cancer Res 61: 7379-7382, 2001.
13. Sarli L, Bottarelli L, Azzoni C, et al: Abnormal Fhit protein expression and high frequency of microsatellite instability in sporadic colorectal cancer. Eur J Cancer 40: 1581-1588, 2004.
14. Koseki K, Takizawa T, Koike M, Ito M, Nihei Z and Sugihara K: Distinction of differentiated type early gastric carcinoma with gastric type mucin expression. Cancer 89: 732-742, 2000.
15. Tajima Y, Shimoda T, Nakanishi Y, et al: Gastric and intestinal phenotypic marker expression in gastric carcinomas and its prognostic significance: inimunohistochemical analysis of 136 lesions. Oncology 61: 212-220, 2001.
16. Kabashima A, Yao T, Sugimachi K and Tsuneyoshi M: Relationship between biologic behavior and phenotypic expression in intramucosal gastric carcinomas. Hum Pathol 33: 80-86, 2002.
17. Kawaguchi K, Yashima K, Koda M, et al: Fhit expression in human gastric adenomas and intramucosal carcinomas: correlation with Mlh1 expression and gastric phenotype. Br J Cancer 90: 672-677, 2004.
18. Reis CA, David L, Correa P, et al: Intestinal metaplasia of human stomach displays distinct patterns of mucin (MUC1, MUC2, MUC5AC, and MUC6) expression. Cancer Res 59: 1003-1007, 1999.
19. Tatematsu M, Tsukamoto T and Inada K: Stem cells and gastric cancer: role of gastric and intestinal mixed intestinal metaplasia. Cancer Sci 94: 135-141, 2003.
20. Tsukamoto T, Inada K, Tanaka H, et al: Down-regulation of a gastric transcription factor, Sox2, and ectopic expression of intestinal homeobox genes, Cdx1 and Cdx2: inverse correlation during progression from gastric/intestinal-mixed to complete intestinal metaplasia. J Cancer Res Clin Oncol 130: 135-145, 2004.
21. Ajioka Y, Watanabe H and Jass JR: MUC1 and MUC2 mucins in flat and polypoid colorectal adenomas. J Clin Pathol 50: 417-421, 1997.
22. Ajioka Y, Allison LJ and Jass JR: Significance of MUC1 and MUC2 mucin expression in colorectal cancer. J Clin Pathol 49: 560-564, 1996.
23. Yao T, Tsutsumi S, Akaiwa Y, Takata M, Nishiyama K, Kabashima A and Tsuneyoshi M: Phenotypic expression of colorectal adenocarcinomas with reference to tumor development and biological behavior. Jpn J Cancer Res 92: 755-761, 2001.
24. Takata M, Yao T, Nishiyama KI, Nawata H and Tsuneyoshi M: Phenotypic alteration in malignant transformation of colonic villous tumours: with special reference to a comparison with tubular tumours. Histopathology 43: 332-339, 2003.
25. Iwase T, Kushima R, Mukaisho K, Mitsuhuzi S, Okanoue T and Hattori T: Overexpression of CD10 and reduced MUC2 expression correlate with the development and progression of colorectal neoplasms. Pathol Res Pract 201: 83-91, 2005.
26. Japanese General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum, and Anus. Japanese Society for Cancer of the Colon and Rectum, 1998.
27. Saitoh Y, Waxman I, West AB, et al: Prevalence and distinctive biologic features of flat colorectal adenomas in a North American polulation. Gastroenterology 120: 1657-1665, 2001.
28. Beak MJ, Kang H, Kim SE, Park JH, Lee JS, Paik YK and Kim H: Expression of hMLH1 is inactivated in the gastric adenomas with enhanced microsatellite instability. Br J Cancer 85: 1147-1152, 2001.
29. Thibodeau SN, French AJ, Roche PC, et al: Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res 56: 4836-4840, 1996.
30. Sozzi G, Pastorino U, Moiraghi L, et al: Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res 58: 5032-5037, 1998.
31. Marcus VA, Madlensky L, Gryfe R, et al: Immunohistochemistry for hMLH1 and hMSH2: a practical test for DNA mismatch repair-deficient. Am J Surg Pathol 23: 1248-1255, 1999.
32. Birrer MJ, Hendricks D, Farley J, Sundborg MJ, Bonome T, Waits MJ and Geradts J: Abnormal Fhit expression in malignant and premalignant lesions of the cervix. Cancer Res 59: 5270-5274, 1999.
33. Mori M, Mimori K, Shiraishi T, et al: Altered expression of Fhit in carcinoma and precarcinomatous lesions of the esophagus. Cancer Res 60: 1177-1182, 2000.
34. Baker SJ, Preisinger AC, Jessup JM, et al: p53 gene mutations occur in combination with 17p allelic delections as late events in colorectal tumorigenesis. Cancer Res 50: 7717-7722, 1990.
35. Ilyas M, Straub J, Tomlinson IPM and Bodmer WF: Genetic pathways in colorectal and other cancers. Eur J Cancer 35: 1986-2002, 1999.
36. Wasa R, Matsukuma S, Abe H, Kuwabara N, Suda K, Arakawwa A and Kitamura S: Histopathological studies of superficial-type early colorectal carcinoma. Cancer 77: 44-50, 1996.
37. Fujimoto Y, Nakanishi Y, Sekine S, Yoshimura K, Akasu T, Moriya Y and Shimoda T: CD10 expression in colorectal carcinoma correlates with liver metastasis. Dis Colon Rectum 48: 1883-1889, 2005.
38. Buisine MP, Janin A, Maunoury V, et al: Aberrant expression of a human mucin gene (MUC5AC) in rectosigmoid villous adenoma. Gastroenterology 110: 84-91, 1996.
39. Mizoshita T, Tsukamoto T, Inada KI, et al: Loss of MUC2 expression correlates with progression along the adenomacarcinoma sequence pathway as well as de nova carcinogenesi in the colon. Histol Histopathol 22: 251-260, 2007.
40. Velcich A, Yang W, Heyer J, et al: Colorectal cancer in mice genetically deficient in the mucin Muc2. Science 295: 1726-1729, 2002.
41. Li A, Goto M, Horinouchi M, et al: Expression of MUC1 and MUC2 mucins and relationship with cell proliferative activity in human colorectal neoplasia. Pathol Int 51: 853-860, 2001.
42. Blank M, Klussmann E, Krasagakes SK, et al: Expression of MUC2-mucin in colorectal adenomas and carcinomas of different histological types. Int J Cancer 59: 301-306, 1994.
43. Bara J, Gautier R, Daher N, Zaghouani H and Decaens C: Monoclonal antibodies against oncofetal mucin M1 antigens associated with precancerous colonic mucosae. Cancer Res 46: 3983-3989, 1986.
44. Bara J, Gautier R, Mouradian P, Decaens C and Daher N: Oncofetal mucin M1 epitope family: characterization and expression during colonic carcinogenesis. Int J Cancer 47: 304-310, 1991.
45. Bartman AE, Sanderson SJ, Ewing SL, Niehans GA, Wiehr CL, Evans MK and Ho SB: Aberrant expression of MUC5AC and MUC6 gastric mucin genes in colorectal polyps. Int J Cancer 80: 210-218, 1999.